Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 421-430 of 10980

Edit search filters
  1. Improving Access to Care Through the Establishment of a Local, Teledermatology Network

    Scottsdale/Phoenix, AZ

  2. INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI

    Rochester, MN

  3. Understanding Post-Traumatic Headache: Forward Translation of a Posttraumatic Headache Animal Model to Posttraumatic Headache in the Human

    Scottsdale/Phoenix, AZ

  4. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

    Rochester, MN

  5. HT-3951 vs. Placebo in Stroke Rehabilitation

    Jacksonville, FL

  6. Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

    Rochester, MN

  7. Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

  8. Technology-enhanced Transitional Palliative Care for Family Caregivers

    Rochester, MN

  9. Development of a Risk Index for Prediction of Health Outcomes and Healthcare Utilization

    Rochester, MN

  10. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer